Is Buying Stock InOnconova Therapeutics Inc. (ONTX) A Good Move Today?

Onconova Therapeutics Inc. (NASDAQ:ONTX) saw an upside of 14.90% on Wednesday at $5.63 after adding $0.73on Wednesday. The 5-day average trading volume is 4,014,595 shares of the company’s common stock. It has gained $6.23 in the past week and touched a new high 3 times within the past 5 days. An average of 1,193,374 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 626,781.

ONTX’s 1-month performance is 5.83% or $1.09 on its low of $4.55 reached on 08/23/21. The company’s shares have touched a 52-week low of $3.60 and high of $28.95, with the stock’s rally to the 52-week high happening on 02/18/21. YTD, ONTX has lost -29.87% or -$1.27 and has reached a new high 6 times. However, the current price is down -80.55%% from the 52-week high price.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Valuation Metrics

ONTX stock has a beta of 1.74. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 368.73 while the price-to-book (PB) in the most recent quarter is 2.34.

Financial Health

Onconova Therapeutics Inc.’s quick ratio for the period ended June 29 was 5.90, with the current ratio over the same period at 5.90 meaning that ONTX stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00. The firm’s gross profit as reported stood at $25.22 million against revenue of $0.23 million.

The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. Onconova Therapeutics Inc.’s return on assets over the past 12 months stands at -62.50%. Return on investment over the past year is -403.20%, while its return on equity (ROE) trailing 12 months is -97.70%. In comparison, the average ROE for the broader industry over the past year is -37.21.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected ONTX to announce -$0.28 per share in earnings in its latest quarter, but it posted -$0.27, representing a 3.60% surprise. EBITDA for the quarter stood at more than -$4.64 million. ONTX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 11.38 million. Shareholders hold equity totaling $15.78 million

Technical Picture

Let’s look briefly at Onconova Therapeutics Inc. (ONTX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 21 September was 68.77% to suggest the stock is trending Neutral, with historical volatility in this time period at 98.37%.

The stock’s 5-day moving average is $5.06, reflecting a +18.22% or $0.88 change from its current price. ONTX is currently trading +13.98% above its 20-day SMA, -46.98% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -1.18% and +18.25% respectively.

Stochastic %K and %D was 33.08% and 26.47% and the average true range (ATR) pointed at 0.41. The RSI (14) points at 62.56%, while the 14-day stochastic is at 66.79% with the period’s ATR at 0.37. The stock’s 9-day MACD Oscillator is pointing at 0.10 and 0.04 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Onconova Therapeutics Inc. (NASDAQ: ONTX), Guggenheim launched coverage with a Buy rating. Analysts offering their rating for ONTX stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate ONTX as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.

What is ONTX’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $11.00 and a high of $29.00, with their median price target at $20.00. Looking at these predictions, the average price target given by analysts is for Onconova Therapeutics Inc. (ONTX) stock is $20.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Articles